Navigation Links
Clinical guide on selective estrogen receptor modulators for postmenopausal osteoporosis

Amsterdam, February 28, 2012 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas. This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as the European Medicines Agency (EMA) has approved the use of bazedoxifene and lasofoxifene.

Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health issues. Various therapies such as bisphosphonates, strontium ranelate and more recently denomsumab are available but these are not suitable for all women. Health concerns have been raised resulting from these therapies, such as oesophageal cancer, osteonecrosis of the jaw (ONJ) and subtrochanteric fractures with bisphosphonates and venous thromboembolism with strontiumranelate. Use of bazedoxifene and lasofoxifene will increase the number of therapeutic options available as these new SERMs point to a greater anti-fracture potential.

The decision of which type of treatment to use for osteoporosis and when to begin should be based on the need to reduce fracture risk. All treatments including SERMs should include recommendations for a healthy life style and adequate calcium and vitamin D intake. Additional benefits of different agents (i.e. climacteric symptom improvement with estrogens, breast cancer prevention for SERMS) must be considered when selecting the anti-osteoporosis drug. Furthermore what agent is used (estrogen, SERM, bisphosphonates) may vary over a woman's life time. The clinical guide from the European Menopause and Andropause Society (EMAS) details all important and necessary aspects of consideration.


Contact: Greyling Peoples

Page: 1

Related biology news :

1. First vaccine against fatal visceral leishmaniasis enters clinical trial
2. Using online patient communities and new trial approaches to optimize clinical research
3. EASL publishes first European Clinical Practice Guidelines for Wilsons disease
4. Verified Clinical Trials System Implemented at Leading Global Contract Research Organization to Improve Participant Safety and Data Integity
5. Ambry Genetics Reports Results from Clinical Diagnostic Exomeâ„¢ Testing of Three Patients
6. HIV/AIDS vaccine developed at Western proceeding to human clinical trials
7. Identify clinically relevant fungi confidently and accurately
8. Global resource for clinical microbiologists and immunologists debuts
9. Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
10. BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
11. Seena clinical trials named for pancreatic cancer advocate
Post Your Comments:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology: